arousal disorder

Neurology
Any parasomnia disorder attributed to an abnormal arousal mechanism with frequent and/or prolonged stress not resolved by a flight-or-fight reaction or relaxation.

Classic arousal disorders
Sleepwalking, sleep terrors, confusional arousals.

Risk factors
Sleep apnoea, heartburn, periodic limb movement during sleep.

Complications
Injury, violence, excess eating, disturbance of bedpartner or family.

Management
Prescription drugs, behaviour modification (e.g., hypnosis or relaxation/mental imagery).

arousal disorder

Sleep disorders Any parasomnia disorder attributed to an abnormal arousal mechanism with frequent and/or prolonged stress Arousal disorders Sleepwalking, sleep terrors, confusional arousals Risk factors Sleep apnea, heartburn, or periodic limb movement during sleep Complications Injury, violence, excess eating, disturbance of bedpartner or family Management Prescription drugs, behavior modification–eg, hypnosis or relaxation/mental imagery. See Adaptation response, Fight-or-flight response. Cf Relaxation response.

a·rous·al dis·or·der

(ă-row'zăl dis-ōr'dĕr)

1. A broad term for parasomnia disorders that range from sleepwalking to sleep terrors; involves a state of being between sleep and wakefulness.

2. A condition or disorder in which normal sexual response is impaired or lacking (e.g., physiologic vaginal lubrication, maintenance of male erection).

Mentioned in ?

References in periodicals archive ?

About HSDD and Sexual Interest and Arousal Disorder

S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder

Instead, it lists female sexual interest/ arousal disorder [FSIAD], which "combines features of HSDD and another condition from the DSM-IV known as female sexual arousal disorder," the FDA pointed out.

Physician certification recommended for flibanserin: drug would be first approval for hyposexual desire disorder in premenopausal women

When associated distress was considered, a survey found the prevalence of hypoactive sexual desire disorder to be 16%, sexual arousal disorder 7%, orgasmic disorder 8%, and dyspareunia 1%.

Female sexual dysfunction

London, March 10 ( ANI ): A woman, from South Carolina, who suffers from Persistent Genital Arousal Disorder that gives her uncontrollable orgasms, has claimed that having orgasms all day might sound like fun but for her, it's a living hell.

Meet woman suffering from arousal disorder who has non-stop orgasms

If the transaction becomes successful, Easton Pharmaceuticals' acquisition will bring the company into the $426-bn a year cosmetics industry to complement its therapeutic line of products including its main product, 'VIORRA', which is a product to treat female sexual arousal disorder.

United States : EASTON Pharmaceuticals to buy anti-ageing and beauty care products line

makers of Eros Therapy[R], the only FDA-cleared medical device for the treatment of female sexual arousal disorder (FSAD), announced a new sales and distribution partnership with Davis-Lobdell Instruments, Inc.

NuGyn, Inc. Announces New Strategic Partner for Eros Therapy[R]: Davis-Lobdell Instruments, Inc.

In such cases, an attended polysomnographic evaluation with time-synchronized video monitoring may help identify nocturnal behaviours associated with an arousal disorder.

Parasomnias: an overview

Through pharmacological reduction of slow wave sleep, as well as potential reduction in the number of transitions between sleep-states, benzodiazepine's reduce the "triggers" that may potentiate the onset of an arousal disorder or RBD episode.

Sleep medicine pharmaceuticals: the treatment of parsomnias

Persistent Genital Arousal Disorder can only be temporarily relieved by one or several orgasms, experts say.

NO PLEASURE IN PASSION BUG

Femprox is NexMed's proprietary cream treatment for female sexual arousal disorder (FSAD).

NEXMED LICENSES FEMPROX TO CJ CORP. FOR SOUTH KOREA

The increase is primarily due to pre-clinical and clinical expenses for our three current R&D projects: ALISTA for female sexual arousal disorder (FSAD), TA-1790 for erectile dysfunction (ED) and VI-0162 for premature ejaculation (PE).

VIVUS REPORTS NET LOSS OF $1.6 MILLION FOR 4TH QTR '02

The study, initiated earlier this year, is being conducted to evaluate the safety and potential efficacy of topically applied ALISTA in subjects with Female Sexual Arousal Disorder (FSAD).